SlideShare uma empresa Scribd logo
1 de 28
 Tanu jaiswal
 Yawar waqar
 Akhil sood
 Debangshu
 Laveena
 Zubair mailk
 Puneet puri
2/18/2012 HAMDARD BUSINESS SCHOOL
1
2/18/2012 HAMDARD BUSINESS SCHOOL
2
2/18/2012 HAMDARD BUSINESS SCHOOL
3
• Abbott Healthcare Private Limited, India
ACQUIRER
• Piramal Healthcare Limited, India
SELLER
• Domestic Formulation Business (including mass market) which
manufactures, markets and sells branded pharmaceutical products in finished
form.
ASSETSACQUIRED
• BusinessTransfer of the Formulation Business into AHPL as a going concern.
MODEOF ACQUISITION
• USD 3.72 billion (approx. INR 175 billion). Upfront payment: USD 2.12 billion
Future payment: USD 400 million payable upon each of the subsequent four
anniversaries of the closing commencing in 2011.
CONSIDERATION
• Cash on the balance sheet of AHPL.
MODEOF FUNDING
2/18/2012 HAMDARD BUSINESS SCHOOL
4
 Abbott is following a Emerging market
penetration strategy.
 Near saturation of the western market is
bringing MNC’s to India.
 This deal would help them give an edge over
their competitors.
 Added attraction: In India, individuals and not
govt pay for a big portion of the healthcare
costs.
2/18/2012 HAMDARD BUSINESS SCHOOL
5
2/18/2012 HAMDARD BUSINESS SCHOOL
6
• TheAbbott-Solvay-Piramal trio would emerge as the undisputed leader in the
lucrative Rs 4,350 crore gastrointestinal market with over 11% share.The trio
would outperform Cadila Healthcare, Dr Reddy’s and Alkem on its way.
Abbott-Solvay-Piramal
• Abbott & Piramal together can form a combined market share of over 8%.The
duo would surpass rival MNCs Novartis, Pfizer,GSK, Merck among host of other
companies.
Vitamins & nutrients
• Piramal holds 6.5% market share in the dermatology segment and with this
acquisitionAbbott will become among the top 5 players solely riding on this
acquisition.
Dermatology Segment
• Abbott-Piramal duo would make solid gains and jump straight to the second
position only trailing Sun Pharma
Neurology Space
• Abbott would gain significant presence riding on Piramal’s strength. In the
segment, whileAbbott figures nowhere in the top 10, Piramal commands a
market share of 5.6% and the sixth position
Core Anti-infectives
2/18/2012 HAMDARD BUSINESS SCHOOL
7
fjjj
Piramal Group
(Promoter Group)
Formulation
Business
Abott Healthcare
Pvt. Ltd.
Piramal
Healthcare Ltd.
Public
Shareholders
Abbott
Laboratories, US
A
100%
47.9%
52.1%
CASH USD
3.72bn
Business
Transfer
2/18/2012
HAMDARD BUSINESS SCHOOL
9
2/18/2012 HAMDARD BUSINESS SCHOOL
10
Target Company Acquirer
DealValue
(USD mn) EV/SALES Mode of Acquisition
Matrix Labs Mylan 736 4.1x Acquired whole company
Ranbaxy Labs Daiichi 4600 6.4x Acquired whole company
Dabur Pharma Fresenius Kabi 273 3.7x Acquired whole company
Santha Biotec Sanofi-Aventis 784 8.7x Acquired whole company
Orchid Chemicals Hospira 400 5x Acquired Injectable business only
Piramal
Healthcare Abbot 3700 8.1x
Acquired domestic formulation
business
2/18/2012 HAMDARD BUSINESS SCHOOL
11
 Net Cash flow= 4616 cr
 Equity share capital= 3358 cr
 Debt= 286.27 cr
 Return on sensex (rm)= 11%
 Beta β= 0.4
 Debt interest rate (rd)= 28%
 Risk free rate (rf )= 7.5
2/18/2012 HAMDARD BUSINESS SCHOOL
12
 Yearly growth rate:
o 1st year: 5.6%
o 2nd year: 10%
o 3rd year: 10%
 Terminal growth rate=2%
 Total number of share= 167210515
2/18/2012 HAMDARD BUSINESS SCHOOL
13
 Per share value = Equity share capital
No. of shares
= 33580000000
167210515
= Rs 200
2/18/2012 HAMDARD BUSINESS SCHOOL
14
Cash flows:
CF1 = 4874.4 Cr
CF2= 5361.84 Cr
CF3= 5898.024 Cr
re= rf +β (rm- rf)
= 7.5 + 0.4(11-7.5)
= 7.5+ 1.4
re = 8.9 % = 9 %
2/18/2012 HAMDARD BUSINESS SCHOOL
15
We* re + Wd* rd
We= E/D+E = 3358 = 3358
3358+286.27 3644.27
Wd= D/D+E = 286.27
3644.27
re= 9% rd= 28%
WACC= 3358 * 9 + 286.27 * 28
3644.27 3644.27
= 0.92*9 + 0.08*28 = 10.54
= 11%
2/18/2012 HAMDARD BUSINESS SCHOOL
16
TerminalValue = CF3* (1+g)
(r-g )
= 5898.024 *(1+0.02)
(.11-.02)
= 5898.024* 11.33
TV = 70490 Cr
Discounted Cash= 4874.4 + 5361.84 + 5898.024
(1+.11) (1+.11)2 (1+.11)3
= 4391+ 4597 + 4573.3
= 13561.3
2/18/2012 HAMDARD BUSINESS SCHOOL
17
DiscountingTV
= 70490 = 51830.8
1.36
EnterpriseValue =TV + CF
= 51830+ 13561.3
= 65391.3
EquityValue = EV-(Debt- Cash)
= 65391.3-(286.27-0)
= 65105.03 Cr
2/18/2012 HAMDARD BUSINESS SCHOOL
18
price per share = 65105.03
167210515
= 389.35
Hence, undervalued
2/18/2012 HAMDARD BUSINESS SCHOOL
19
Particulars Amount
Up Front Payment (US $mn) 2120
NPV of Future Payments 400mn US $ for 4 years
from 2011 (Discounted at 10%) 1268
PVTotal Reciepts (US $ mn) 3388
PVTotal Payments (cr) 15856
Additional PaymentTo PEL(Rs) 350
EV/SALESValuation 8.1
2/18/2012 HAMDARD BUSINESS SCHOOL
20
 Current valuation of the deal is at 6.6x and 5.5x on basis of FY11e and FY12E sales.
 We see the valuation of Piramal’s DFB at 7x on basis of FY10 sales.
 The CompaniesAct, 1956
 Securities and Exchange Board of India
(SEBI)Takeover Code
 Foreign Exchange ManagementAct, 1999.
 CompetitionAct, 2000
2/18/2012 HAMDARD BUSINESS SCHOOL
21
Big Pharma companies has three big
problems —
 Its most important drugs are losing patent
protection, growth in developed markets is
slowing to a crawl, and much of its cash is
trapped overseas
 Abbott’s purchase of India’s Piramal
Healthcare’s generic drugs business for $3.7
billion offers a partial answer to all three
variables.
 Six of the world’s ten biggest drugs are likely
to lose U.S. patent protection by the end of
2012.
2/18/2012 HAMDARD BUSINESS SCHOOL
22
 Other major markets in Europe andAsia are
on similar timetables.The value of many big
franchises will be gutted as cheaper versions
of these compounds are introduced.
 As a result, growth of drug sales in developed
countries is likely to be between 3 and 6
percent over the next several
years, according to IMS.
2/18/2012 HAMDARD BUSINESS SCHOOL
23
 Of course, big drugs companies can console themselves with the fact
their businesses still generate substantial profits and cashflow.The
trouble is that much of this comes from foreign subsidiaries, where it
remains stashed away. Repatriating the cash to pay investors dividends
or buy back stock would generate a large tax bill.
 One way to deal with these myriad problems is to move into the generics
business, as Novartis , Sanofi-Aventis andAbbott have.
 Another is to expand into emerging markets. India, for example, is
growing about three times as fast as developed markets, and given the
state of medical care there, it is unlikely to slow any time soon.
 A third response is for drug makers to put their stashed cash to work
overseas buying foreign companies.
2/18/2012 HAMDARD BUSINESS SCHOOL
24
Unfortunately for Abbott, the answer doesn’t come cheap.
Piramal’s sales this year should be above $500 million, according
to the company.While Abbott’s only paying a chunk of the cash
over several years, the net present value is still 6.4 times trailing
sales.The typical generic company goes for around 3.5
times, according to Credit Suisse.
Abbott’s deal has other attractions.
 The return on the investment appears rather low, but is probably
better than leaving the funds smoldering in a bank. Moreover, the
Piramal business gives Abbott scale in India.With a population
greater than a billion, and the proportion that can afford medicine
rising rapidly, that’s a pretty good place to be.
2/18/2012 HAMDARD BUSINESS SCHOOL
25
 Cross-border mergers place Indian
companies on the global map.
 Being a significant part of the global
pharmaceutical sector will help the Indian
companies to take further steps in
maintaining the global pharmaceutical
standards
 Including exports, increased profitability,
increase in the R&D laboratories, funding
received by the companies, increased
number of patented products, expansion of
their market share etc.
2/18/2012 HAMDARD BUSINESS SCHOOL
26
 This in turn will be beneficial to the global
pharmaceuticals as well since the cost effective
techniques used by Indian companies and the huge
market India provides to this sector can help enhance
the research and creation of newer and improved
drugs.
 Although there always remains the risk of losing
individual identity of such companies or exposing the
industry to a threat of rampant takeovers, on the
whole Mergers elevates the economic graph of the
country.
2/18/2012 HAMDARD BUSINESS SCHOOL
27
THANKYOU !
2/18/2012 HAMDARD BUSINESS SCHOOL
28

Mais conteúdo relacionado

Mais procurados

IQVIA- Q3 2022 Industry Presentation.pdf
IQVIA- Q3 2022 Industry Presentation.pdfIQVIA- Q3 2022 Industry Presentation.pdf
IQVIA- Q3 2022 Industry Presentation.pdfAliShahid755835
 
DABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITED
DABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITEDDABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITED
DABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITEDSneha Malhotra
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryYee Jie NG
 
Marketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun PharmaceuticalsMarketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun PharmaceuticalsAman Dube
 
Presentation on cipla project
Presentation on cipla projectPresentation on cipla project
Presentation on cipla projectPratyush Mishra
 
Analysis of pharmaceutical Industry based on porters five forces model
Analysis of pharmaceutical Industry based on porters five forces model Analysis of pharmaceutical Industry based on porters five forces model
Analysis of pharmaceutical Industry based on porters five forces model Ekankita Agrawalla
 
Nimalox re-branding marketing plan
Nimalox re-branding marketing planNimalox re-branding marketing plan
Nimalox re-branding marketing planMahmoUd Nasa
 
Mankind corporate presentation
Mankind corporate presentationMankind corporate presentation
Mankind corporate presentationAnkit Khandelewal
 
Marketing Plan Final
Marketing Plan FinalMarketing Plan Final
Marketing Plan FinalTeeka
 
Working Capital Management on Cadila Healthcare Limited.
Working Capital Management on Cadila Healthcare Limited.Working Capital Management on Cadila Healthcare Limited.
Working Capital Management on Cadila Healthcare Limited.Moin Panja
 
10 step marketing plan for aforvir
10 step marketing plan for aforvir10 step marketing plan for aforvir
10 step marketing plan for aforvirRalph Raymund Pinon
 
Impact of mergers and acquisition of pharmaceutical industry in indian scenario
Impact of mergers and acquisition of pharmaceutical industry in indian scenarioImpact of mergers and acquisition of pharmaceutical industry in indian scenario
Impact of mergers and acquisition of pharmaceutical industry in indian scenarioNitin Patel
 
Neoslim™ Final
Neoslim™ FinalNeoslim™ Final
Neoslim™ Finalghoshk
 
Novartis - Strategy Memo
Novartis - Strategy MemoNovartis - Strategy Memo
Novartis - Strategy MemoRheetam Mitra
 
flip-kart case study and SWAT analysis after merge Walmart
flip-kart case study and SWAT analysis after merge Walmart flip-kart case study and SWAT analysis after merge Walmart
flip-kart case study and SWAT analysis after merge Walmart AnubhavMishra70
 

Mais procurados (20)

IQVIA- Q3 2022 Industry Presentation.pdf
IQVIA- Q3 2022 Industry Presentation.pdfIQVIA- Q3 2022 Industry Presentation.pdf
IQVIA- Q3 2022 Industry Presentation.pdf
 
Cipla
CiplaCipla
Cipla
 
DABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITED
DABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITEDDABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITED
DABUR INDIA LIMITED ACQUISITION OF FEM CARE PHARMA LIMITED
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical Industry
 
Sun Pharma
Sun Pharma Sun Pharma
Sun Pharma
 
Marketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun PharmaceuticalsMarketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun Pharmaceuticals
 
Presentation on cipla project
Presentation on cipla projectPresentation on cipla project
Presentation on cipla project
 
Analysis of pharmaceutical Industry based on porters five forces model
Analysis of pharmaceutical Industry based on porters five forces model Analysis of pharmaceutical Industry based on porters five forces model
Analysis of pharmaceutical Industry based on porters five forces model
 
Nimalox re-branding marketing plan
Nimalox re-branding marketing planNimalox re-branding marketing plan
Nimalox re-branding marketing plan
 
Mankind corporate presentation
Mankind corporate presentationMankind corporate presentation
Mankind corporate presentation
 
Marketing Plan Final
Marketing Plan FinalMarketing Plan Final
Marketing Plan Final
 
Esomeprazole plan
Esomeprazole planEsomeprazole plan
Esomeprazole plan
 
Working Capital Management on Cadila Healthcare Limited.
Working Capital Management on Cadila Healthcare Limited.Working Capital Management on Cadila Healthcare Limited.
Working Capital Management on Cadila Healthcare Limited.
 
10 step marketing plan for aforvir
10 step marketing plan for aforvir10 step marketing plan for aforvir
10 step marketing plan for aforvir
 
Impact of mergers and acquisition of pharmaceutical industry in indian scenario
Impact of mergers and acquisition of pharmaceutical industry in indian scenarioImpact of mergers and acquisition of pharmaceutical industry in indian scenario
Impact of mergers and acquisition of pharmaceutical industry in indian scenario
 
Neoslim™ Final
Neoslim™ FinalNeoslim™ Final
Neoslim™ Final
 
Generic Drugs
Generic Drugs Generic Drugs
Generic Drugs
 
Novartis - Strategy Memo
Novartis - Strategy MemoNovartis - Strategy Memo
Novartis - Strategy Memo
 
Zydus
ZydusZydus
Zydus
 
flip-kart case study and SWAT analysis after merge Walmart
flip-kart case study and SWAT analysis after merge Walmart flip-kart case study and SWAT analysis after merge Walmart
flip-kart case study and SWAT analysis after merge Walmart
 

Semelhante a Abbott piramal outlook

Dr.reddy labs financial analysis
Dr.reddy labs financial analysisDr.reddy labs financial analysis
Dr.reddy labs financial analysisTakur Singh
 
Bcg Matrix + Porters Five Force Model - Anuj Gandhi
Bcg Matrix + Porters Five Force Model - Anuj GandhiBcg Matrix + Porters Five Force Model - Anuj Gandhi
Bcg Matrix + Porters Five Force Model - Anuj GandhiAnuj Gandhi
 
Pharmaceuticals in india
Pharmaceuticals in indiaPharmaceuticals in india
Pharmaceuticals in indiaPragya Dixit
 
Fin301 Term Paper - The Drug Scene
Fin301 Term Paper - The Drug SceneFin301 Term Paper - The Drug Scene
Fin301 Term Paper - The Drug SceneSamiya Yesmin
 
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Daniel Grunstein
 
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...Nikhil Dhawan
 
A review of marketing
A review of marketingA review of marketing
A review of marketingNilesh Shah
 
A review of marketing
A review of marketingA review of marketing
A review of marketingNilesh Shah
 
Dr Reddy's Initiating Coverage
Dr Reddy's Initiating CoverageDr Reddy's Initiating Coverage
Dr Reddy's Initiating CoverageGaurav Singh
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalAnup Soans
 
Contract Manufacturing In India
Contract Manufacturing  In IndiaContract Manufacturing  In India
Contract Manufacturing In Indiakaushik2541984
 
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crHem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crIndiaNotes.com
 
4th annual pharmaceutical leadership summit
4th  annual pharmaceutical leadership summit4th  annual pharmaceutical leadership summit
4th annual pharmaceutical leadership summitpharmaleaders
 
4th annual pharmaceutical leadership summit
4th  annual pharmaceutical leadership summit4th  annual pharmaceutical leadership summit
4th annual pharmaceutical leadership summitIndian Affairs
 
4th annual pharmaceutical leadership summit
4th  annual pharmaceutical leadership summit4th  annual pharmaceutical leadership summit
4th annual pharmaceutical leadership summitIndian Affairs
 

Semelhante a Abbott piramal outlook (20)

Dr.reddy labs financial analysis
Dr.reddy labs financial analysisDr.reddy labs financial analysis
Dr.reddy labs financial analysis
 
Bcg Matrix + Porters Five Force Model - Anuj Gandhi
Bcg Matrix + Porters Five Force Model - Anuj GandhiBcg Matrix + Porters Five Force Model - Anuj Gandhi
Bcg Matrix + Porters Five Force Model - Anuj Gandhi
 
Pharmaceuticals in india
Pharmaceuticals in indiaPharmaceuticals in india
Pharmaceuticals in india
 
Fin301 Term Paper - The Drug Scene
Fin301 Term Paper - The Drug SceneFin301 Term Paper - The Drug Scene
Fin301 Term Paper - The Drug Scene
 
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
 
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...
 
Jefferies pharma (1)
Jefferies   pharma (1)Jefferies   pharma (1)
Jefferies pharma (1)
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
Dr Reddy's Initiating Coverage
Dr Reddy's Initiating CoverageDr Reddy's Initiating Coverage
Dr Reddy's Initiating Coverage
 
DSP Healthcare Fund
DSP Healthcare FundDSP Healthcare Fund
DSP Healthcare Fund
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit Ghoshal
 
Indian Pharma-36.pdf
Indian Pharma-36.pdfIndian Pharma-36.pdf
Indian Pharma-36.pdf
 
PowerPoint Presentation
PowerPoint Presentation PowerPoint Presentation
PowerPoint Presentation
 
Contract Manufacturing In India
Contract Manufacturing  In IndiaContract Manufacturing  In India
Contract Manufacturing In India
 
Daily equity report
Daily equity reportDaily equity report
Daily equity report
 
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crHem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87cr
 
4th annual pharmaceutical leadership summit
4th  annual pharmaceutical leadership summit4th  annual pharmaceutical leadership summit
4th annual pharmaceutical leadership summit
 
4th annual pharmaceutical leadership summit
4th  annual pharmaceutical leadership summit4th  annual pharmaceutical leadership summit
4th annual pharmaceutical leadership summit
 
4th annual pharmaceutical leadership summit
4th  annual pharmaceutical leadership summit4th  annual pharmaceutical leadership summit
4th annual pharmaceutical leadership summit
 

Último

Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for BusinessQ2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for BusinessAPCO
 
Fabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsFabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsWristbands Ireland
 
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...Brian Solis
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...Khaled Al Awadi
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxJemalSeid25
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024Stephan Koning
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHelene Heckrotte
 
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfGraham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfAnhNguyen97152
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinAnton Skornyakov
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfHajeJanKamps
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toumarfarooquejamali32
 
Live-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarLive-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarNathanielSchmuck
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.ukaroemirsr
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursKaiNexus
 

Último (20)

Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for BusinessQ2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
Q2 2024 APCO Geopolitical Radar - The Global Operating Environment for Business
 
Fabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsFabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and Festivals
 
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
The End of Business as Usual: Rewire the Way You Work to Succeed in the Consu...
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptx
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
 
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdfGraham and Doddsville - Issue 1 - Winter 2006 (1).pdf
Graham and Doddsville - Issue 1 - Winter 2006 (1).pdf
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup Berlin
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdf
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
WAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdfWAM Corporate Presentation Mar 25 2024.pdf
WAM Corporate Presentation Mar 25 2024.pdf
 
Lecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb toLecture_6.pptx English speaking easyb to
Lecture_6.pptx English speaking easyb to
 
Live-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry WebinarLive-Streaming in the Music Industry Webinar
Live-Streaming in the Music Industry Webinar
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.uk
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, Ours
 

Abbott piramal outlook

  • 1.  Tanu jaiswal  Yawar waqar  Akhil sood  Debangshu  Laveena  Zubair mailk  Puneet puri 2/18/2012 HAMDARD BUSINESS SCHOOL 1
  • 4. • Abbott Healthcare Private Limited, India ACQUIRER • Piramal Healthcare Limited, India SELLER • Domestic Formulation Business (including mass market) which manufactures, markets and sells branded pharmaceutical products in finished form. ASSETSACQUIRED • BusinessTransfer of the Formulation Business into AHPL as a going concern. MODEOF ACQUISITION • USD 3.72 billion (approx. INR 175 billion). Upfront payment: USD 2.12 billion Future payment: USD 400 million payable upon each of the subsequent four anniversaries of the closing commencing in 2011. CONSIDERATION • Cash on the balance sheet of AHPL. MODEOF FUNDING 2/18/2012 HAMDARD BUSINESS SCHOOL 4
  • 5.  Abbott is following a Emerging market penetration strategy.  Near saturation of the western market is bringing MNC’s to India.  This deal would help them give an edge over their competitors.  Added attraction: In India, individuals and not govt pay for a big portion of the healthcare costs. 2/18/2012 HAMDARD BUSINESS SCHOOL 5
  • 7. • TheAbbott-Solvay-Piramal trio would emerge as the undisputed leader in the lucrative Rs 4,350 crore gastrointestinal market with over 11% share.The trio would outperform Cadila Healthcare, Dr Reddy’s and Alkem on its way. Abbott-Solvay-Piramal • Abbott & Piramal together can form a combined market share of over 8%.The duo would surpass rival MNCs Novartis, Pfizer,GSK, Merck among host of other companies. Vitamins & nutrients • Piramal holds 6.5% market share in the dermatology segment and with this acquisitionAbbott will become among the top 5 players solely riding on this acquisition. Dermatology Segment • Abbott-Piramal duo would make solid gains and jump straight to the second position only trailing Sun Pharma Neurology Space • Abbott would gain significant presence riding on Piramal’s strength. In the segment, whileAbbott figures nowhere in the top 10, Piramal commands a market share of 5.6% and the sixth position Core Anti-infectives 2/18/2012 HAMDARD BUSINESS SCHOOL 7
  • 8. fjjj Piramal Group (Promoter Group) Formulation Business Abott Healthcare Pvt. Ltd. Piramal Healthcare Ltd. Public Shareholders Abbott Laboratories, US A 100% 47.9% 52.1% CASH USD 3.72bn Business Transfer
  • 11. Target Company Acquirer DealValue (USD mn) EV/SALES Mode of Acquisition Matrix Labs Mylan 736 4.1x Acquired whole company Ranbaxy Labs Daiichi 4600 6.4x Acquired whole company Dabur Pharma Fresenius Kabi 273 3.7x Acquired whole company Santha Biotec Sanofi-Aventis 784 8.7x Acquired whole company Orchid Chemicals Hospira 400 5x Acquired Injectable business only Piramal Healthcare Abbot 3700 8.1x Acquired domestic formulation business 2/18/2012 HAMDARD BUSINESS SCHOOL 11
  • 12.  Net Cash flow= 4616 cr  Equity share capital= 3358 cr  Debt= 286.27 cr  Return on sensex (rm)= 11%  Beta β= 0.4  Debt interest rate (rd)= 28%  Risk free rate (rf )= 7.5 2/18/2012 HAMDARD BUSINESS SCHOOL 12
  • 13.  Yearly growth rate: o 1st year: 5.6% o 2nd year: 10% o 3rd year: 10%  Terminal growth rate=2%  Total number of share= 167210515 2/18/2012 HAMDARD BUSINESS SCHOOL 13
  • 14.  Per share value = Equity share capital No. of shares = 33580000000 167210515 = Rs 200 2/18/2012 HAMDARD BUSINESS SCHOOL 14
  • 15. Cash flows: CF1 = 4874.4 Cr CF2= 5361.84 Cr CF3= 5898.024 Cr re= rf +β (rm- rf) = 7.5 + 0.4(11-7.5) = 7.5+ 1.4 re = 8.9 % = 9 % 2/18/2012 HAMDARD BUSINESS SCHOOL 15
  • 16. We* re + Wd* rd We= E/D+E = 3358 = 3358 3358+286.27 3644.27 Wd= D/D+E = 286.27 3644.27 re= 9% rd= 28% WACC= 3358 * 9 + 286.27 * 28 3644.27 3644.27 = 0.92*9 + 0.08*28 = 10.54 = 11% 2/18/2012 HAMDARD BUSINESS SCHOOL 16
  • 17. TerminalValue = CF3* (1+g) (r-g ) = 5898.024 *(1+0.02) (.11-.02) = 5898.024* 11.33 TV = 70490 Cr Discounted Cash= 4874.4 + 5361.84 + 5898.024 (1+.11) (1+.11)2 (1+.11)3 = 4391+ 4597 + 4573.3 = 13561.3 2/18/2012 HAMDARD BUSINESS SCHOOL 17
  • 18. DiscountingTV = 70490 = 51830.8 1.36 EnterpriseValue =TV + CF = 51830+ 13561.3 = 65391.3 EquityValue = EV-(Debt- Cash) = 65391.3-(286.27-0) = 65105.03 Cr 2/18/2012 HAMDARD BUSINESS SCHOOL 18
  • 19. price per share = 65105.03 167210515 = 389.35 Hence, undervalued 2/18/2012 HAMDARD BUSINESS SCHOOL 19
  • 20. Particulars Amount Up Front Payment (US $mn) 2120 NPV of Future Payments 400mn US $ for 4 years from 2011 (Discounted at 10%) 1268 PVTotal Reciepts (US $ mn) 3388 PVTotal Payments (cr) 15856 Additional PaymentTo PEL(Rs) 350 EV/SALESValuation 8.1 2/18/2012 HAMDARD BUSINESS SCHOOL 20  Current valuation of the deal is at 6.6x and 5.5x on basis of FY11e and FY12E sales.  We see the valuation of Piramal’s DFB at 7x on basis of FY10 sales.
  • 21.  The CompaniesAct, 1956  Securities and Exchange Board of India (SEBI)Takeover Code  Foreign Exchange ManagementAct, 1999.  CompetitionAct, 2000 2/18/2012 HAMDARD BUSINESS SCHOOL 21
  • 22. Big Pharma companies has three big problems —  Its most important drugs are losing patent protection, growth in developed markets is slowing to a crawl, and much of its cash is trapped overseas  Abbott’s purchase of India’s Piramal Healthcare’s generic drugs business for $3.7 billion offers a partial answer to all three variables.  Six of the world’s ten biggest drugs are likely to lose U.S. patent protection by the end of 2012. 2/18/2012 HAMDARD BUSINESS SCHOOL 22
  • 23.  Other major markets in Europe andAsia are on similar timetables.The value of many big franchises will be gutted as cheaper versions of these compounds are introduced.  As a result, growth of drug sales in developed countries is likely to be between 3 and 6 percent over the next several years, according to IMS. 2/18/2012 HAMDARD BUSINESS SCHOOL 23
  • 24.  Of course, big drugs companies can console themselves with the fact their businesses still generate substantial profits and cashflow.The trouble is that much of this comes from foreign subsidiaries, where it remains stashed away. Repatriating the cash to pay investors dividends or buy back stock would generate a large tax bill.  One way to deal with these myriad problems is to move into the generics business, as Novartis , Sanofi-Aventis andAbbott have.  Another is to expand into emerging markets. India, for example, is growing about three times as fast as developed markets, and given the state of medical care there, it is unlikely to slow any time soon.  A third response is for drug makers to put their stashed cash to work overseas buying foreign companies. 2/18/2012 HAMDARD BUSINESS SCHOOL 24
  • 25. Unfortunately for Abbott, the answer doesn’t come cheap. Piramal’s sales this year should be above $500 million, according to the company.While Abbott’s only paying a chunk of the cash over several years, the net present value is still 6.4 times trailing sales.The typical generic company goes for around 3.5 times, according to Credit Suisse. Abbott’s deal has other attractions.  The return on the investment appears rather low, but is probably better than leaving the funds smoldering in a bank. Moreover, the Piramal business gives Abbott scale in India.With a population greater than a billion, and the proportion that can afford medicine rising rapidly, that’s a pretty good place to be. 2/18/2012 HAMDARD BUSINESS SCHOOL 25
  • 26.  Cross-border mergers place Indian companies on the global map.  Being a significant part of the global pharmaceutical sector will help the Indian companies to take further steps in maintaining the global pharmaceutical standards  Including exports, increased profitability, increase in the R&D laboratories, funding received by the companies, increased number of patented products, expansion of their market share etc. 2/18/2012 HAMDARD BUSINESS SCHOOL 26
  • 27.  This in turn will be beneficial to the global pharmaceuticals as well since the cost effective techniques used by Indian companies and the huge market India provides to this sector can help enhance the research and creation of newer and improved drugs.  Although there always remains the risk of losing individual identity of such companies or exposing the industry to a threat of rampant takeovers, on the whole Mergers elevates the economic graph of the country. 2/18/2012 HAMDARD BUSINESS SCHOOL 27
  • 28. THANKYOU ! 2/18/2012 HAMDARD BUSINESS SCHOOL 28

Notas do Editor

  1. A private limited company, incorporated under the Companies Act, 1956 (“Companies Act”) on January 1, 1997. AHPL is a wholly owned direct subsidiary of Abbott Lab and is into manufacture and saleofallopathic pharmaceutical preparations; sale of chemicals, scientific, medical & surgical instruments / equipment / devices, and nutritional products.
  2. Piramal is a 22 year old pharma company, which is one of the earliest players of theindianpharmamarket.Through strategic acquisitions in the early years, Piramal healthcare has developed an enviable position in the Indian pharma sector. It is incorporated under the Companies Act and is currently listed on Bombay Stock Exchange Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”). The promoter holding in Piramal Healthcare is currently around 52.10%.